State Street SPDR S&P Pharmaceuticals ETF (XPH) Fund Overview

State Street SPDR S&P Pharmaceuticals ETF (XPH) Financial Services Profile

State Street SPDR S&P Pharmaceuticals ETF (XPH) provides targeted exposure to the pharmaceuticals segment of the S&P TMI, tracking a modified equal-weighted index. This ETF allows investors to strategically position themselves within the pharmaceutical industry, offering diversified exposure across large, mid, and small-cap stocks.

What Is the Investment Thesis for XPH?

The State Street SPDR S&P Pharmaceuticals ETF (XPH), with a market capitalization of $0.22 billion and a beta of 0.89, offers a targeted investment in the pharmaceutical sector. The ETF's modified equal-weighted approach provides diversification across large, mid, and small-cap pharmaceutical companies. A key value driver is the potential for growth in the pharmaceutical industry, driven by factors such as aging populations, increasing healthcare spending, and advancements in drug development. Upcoming catalysts include potential breakthroughs in pharmaceutical research and development, regulatory approvals for new drugs, and expansion into emerging markets. Potential risks include regulatory changes, patent expirations, and increased competition from generic drug manufacturers. While the ETF does not offer a dividend yield, its potential for capital appreciation makes it a noteworthy option for investors seeking exposure to the pharmaceutical sector.

Based on FMP financials and quantitative analysis

XPH Key Highlights

Market capitalization of $0.22 billion, indicating a relatively small ETF focused on a specific sector.

• Beta of 0.89 suggests the ETF is slightly less volatile than the broader market.
• The ETF tracks the S&P Pharmaceuticals Select Industry Index, providing targeted exposure to the pharmaceutical sector.
• Modified equal-weighted index aims to provide diversification across large, mid, and small-cap stocks within the pharmaceutical industry.
• Absence of dividend yield may appeal to growth-oriented investors rather than income-seeking investors.

Who Are XPH's Competitors?

XPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XPH's Key Strengths?

Targeted exposure to the pharmaceutical sector.

• Diversification across large, mid, and small-cap stocks.
• Modified equal-weighted index methodology.
• Low expense ratio.

What Are XPH's Weaknesses?

Sector-specific focus may lead to higher volatility.

• Lack of dividend yield may not appeal to all investors.
• Performance is tied to the performance of the S&P Pharmaceuticals Select Industry Index.

What Are the Key Risks for XPH?

Regulatory changes and patent expirations.

• Increased competition from generic drug manufacturers.
• Economic downturns that could reduce healthcare spending.
• Sector-specific focus may lead to higher volatility.
• Dependence on the performance of the S&P Pharmaceuticals Select Industry Index.

What Are XPH's Competitive Advantages?

• Established brand name and reputation of State Street.
• Low expense ratio compared to actively managed funds.
• Diversification benefits through exposure to a basket of pharmaceutical stocks.

What Does XPH Do?

The State Street SPDR S&P Pharmaceuticals ETF (XPH) was created to mirror the investment results, before accounting for fees and expenses, of the S&P Pharmaceuticals Select Industry Index. This index represents the pharmaceuticals sub-industry within the broader S&P Total Market Index (TMI). By tracking a modified equal-weighted index, XPH aims to provide investors with a less concentrated exposure to the pharmaceutical sector, diversifying holdings across companies of varying market capitalizations, including large-cap, mid-cap, and small-cap stocks. The ETF's structure allows investors to implement strategic or tactical investment approaches with a more focused lens than traditional sector-based investing. XPH's methodology seeks to avoid over-reliance on any single company's performance, potentially mitigating risk and providing a more balanced representation of the pharmaceutical industry's overall performance. The fund's objective is to offer a convenient and cost-effective way for investors to gain exposure to a basket of pharmaceutical companies without directly purchasing individual stocks. State Street, a well-established financial institution, manages the ETF, leveraging its expertise in investment management and ETF administration to provide investors with a reliable and transparent investment vehicle. As of 2026, XPH continues to serve as a tool for investors seeking to fine-tune their sector allocations and capitalize on the growth potential within the pharmaceuticals industry.

What Products and Services Does XPH Offer?

• Tracks the performance of the S&P Pharmaceuticals Select Industry Index.
• Provides exposure to the pharmaceuticals segment of the S&P TMI.
• Utilizes a modified equal-weighted index methodology.
• Offers diversification across large, mid, and small-cap pharmaceutical stocks.
• Allows investors to take strategic or tactical positions in the pharmaceutical sector.
• Provides a cost-effective way to invest in a basket of pharmaceutical companies.
• Offers transparency in its holdings and investment strategy.

How Does XPH Make Money?

• Generates revenue through management fees charged to investors.
• Fees are based on a percentage of the ETF's assets under management (AUM).
• Aims to provide investment results that correspond to the performance of its benchmark index.

What Industry Does XPH Operate In?

The State Street SPDR S&P Pharmaceuticals ETF (XPH) operates within the asset management industry, specifically focusing on providing exposure to the pharmaceutical sector. The pharmaceutical industry is driven by factors such as aging populations, increasing healthcare spending, and advancements in drug development. The competitive landscape includes other ETFs and mutual funds that also focus on the healthcare or pharmaceutical sectors. XPH differentiates itself through its modified equal-weighted approach, which aims to provide diversification across companies of varying market capitalizations.

Who Are XPH's Key Customers?

• Retail investors seeking exposure to the pharmaceutical sector.
• Institutional investors looking for a cost-effective way to diversify their portfolios.
• Financial advisors seeking to provide their clients with targeted sector exposure.

XPH Financials

XPH Latest News

XPH Analyst Consensus

XPH MoonshotScore

Common Questions About XPH (Financials)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources